We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Maria Garzon

Maria C. Garzon MD

Professor of Dermatology and Pediatrics, Columbia University Irving Medical Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

Disclosures

Dr. Garzon reports the following:
  • Investigator: NICHD-2015-TIM01 Pediatric Trials Network Topical Timolol Study
    • Multi-center, double-masked randomized, efficacy, safety and pharmacokinetic (PK) study to assess the safety and efficacy of 0.25% and 0.5% topical timolol gel-forming solution in infants between the ages of 0-84 days
  • Co-Investigator: Astellas Pharma Inc US, Deerfield, IL APPLES
    • Apples: A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis